Hemant Malhotra

Jaipur, RJ, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

Journal: The New England journal of medicine

Published: March 25, 2026

Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice.

Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice.

Journal: Expert review of hematology

Published: December 29, 2025

Dynamic 18 F-PSMA-1007 PET-CT kinetics as a prognostic marker in newly diagnosed prostate cancer: a prospective pilot study.

Dynamic 18 F-PSMA-1007 PET-CT kinetics as a prognostic marker in newly diagnosed prostate cancer: a prospective pilot study.

Journal: World journal of urology

Published: October 29, 2025

Clinical and Molecular Profiles and Treatment Outcomes in Patients With Acute Promyelocytic Leukaemia: A Single-Centre Experience.

Clinical and Molecular Profiles and Treatment Outcomes in Patients With Acute Promyelocytic Leukaemia: A Single-Centre Experience.

Journal: Cureus

Published: September 14, 2025

Isolated Cubital Node Metastasis in a Treated Case of Breast Carcinoma on 18F-FDG PET/CT: A Rare Finding.

Isolated Cubital Node Metastasis in a Treated Case of Breast Carcinoma on 18F-FDG PET/CT: A Rare Finding.

Journal: Journal of nuclear medicine technology

Published: August 26, 2025

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 04, 2025

Is 18F-PSMA PET/CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?

Is 18F-PSMA PET/CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?

Journal: Journal of neuro-oncology

Published: June 15, 2025

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Journal: Leukemia

Published: May 29, 2025

Management of chronic myeloid leukemia in 2025.

Management of chronic myeloid leukemia in 2025.

Journal: Cancer

Published: April 18, 2025

Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC).

Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC).

Journal: South Asian journal of cancer

Published: March 24, 2025

Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure.

Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure.

Journal: South Asian journal of cancer

Published: November 22, 2024

Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial.

Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial.

Journal: JCO global oncology

Published: November 14, 2024

Showing 1-12 of 50

Last Updated: 09/26/2026